[go: up one dir, main page]

WO2010087981A3 - Dérivés amides bicycliques permettant d'améliorer les réponses synaptiques glutamatergiques - Google Patents

Dérivés amides bicycliques permettant d'améliorer les réponses synaptiques glutamatergiques Download PDF

Info

Publication number
WO2010087981A3
WO2010087981A3 PCT/US2010/000255 US2010000255W WO2010087981A3 WO 2010087981 A3 WO2010087981 A3 WO 2010087981A3 US 2010000255 W US2010000255 W US 2010000255W WO 2010087981 A3 WO2010087981 A3 WO 2010087981A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
treatment
disorders
compounds
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000255
Other languages
English (en)
Other versions
WO2010087981A2 (fr
Inventor
Rudolf Mueller
Leslie J. Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI1005316A priority Critical patent/BRPI1005316A2/pt
Priority to JP2011547981A priority patent/JP2012516845A/ja
Priority to EP10736150A priority patent/EP2391621A4/fr
Priority to MX2011008060A priority patent/MX2011008060A/es
Priority to EA201101162A priority patent/EA018994B1/ru
Priority to AU2010208646A priority patent/AU2010208646A1/en
Priority to CN2010800154033A priority patent/CN102369201A/zh
Priority to SG2011054376A priority patent/SG173168A1/en
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Priority to CA2751285A priority patent/CA2751285A1/fr
Publication of WO2010087981A2 publication Critical patent/WO2010087981A2/fr
Publication of WO2010087981A3 publication Critical patent/WO2010087981A3/fr
Priority to IL214392A priority patent/IL214392A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiques et des méthodes destinés à être utilisés dans la prévention et le traitement de l'insuffisance cérébrale, y compris pour améliorer le fonctionnement des récepteurs dans les synapses des réseaux cérébraux responsables de comportements basiques et d'ordres supérieurs. Ces réseaux cérébraux, qui sont impliqués dans des capacités cognitives liées à un affaiblissement de la mémoire, tel que celui qu'on observe dans un certain nombre de démences, dans des déséquilibres de l'activité neuronale entre différentes régions du cerveau, comme le suggèrent les troubles tels que la maladie de Parkinson, la schizophrénie, l'apnée du sommeil, le trouble de déficit de l'attention et les troubles affectifs ou de l'humeur et dans les troubles dans lesquels une déficience en facteurs neurotrophiques est impliquée, ainsi que des conditions tels que l'apnée centrale du sommeil induite par un accident vasculaire cérébral, l'apnée obstructive du sommeil, le syndrome d'hypoventilation congénital, le syndrome d'hypoventilation liée à l'obésité, le syndrome de la mort subite du nourrisson, le syndrome de Rett, la lésion médullaire, la lésion cérébrale traumatique, la respiration de Cheney-Stokes, le syndrome d'Ondine, le syndrome de Prader-Willi et la noyade. Dans un aspect particulier, cette invention porte sur des composés amides bicycliques utiles pour le traitement de tels états et des méthodes d'utilisation de ces composés pour un tel traitement.
PCT/US2010/000255 2009-02-02 2010-01-29 Dérivés amides bicycliques permettant d'améliorer les réponses synaptiques glutamatergiques Ceased WO2010087981A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2010800154033A CN102369201A (zh) 2009-02-02 2010-01-29 增强谷氨酸能突触响应的二环酰胺衍生物
EP10736150A EP2391621A4 (fr) 2009-02-02 2010-01-29 Dérivés amides bicycliques permettant d'améliorer les réponses synaptiques glutamatergiques
MX2011008060A MX2011008060A (es) 2009-02-02 2010-01-29 Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
EA201101162A EA018994B1 (ru) 2009-02-02 2010-01-29 Производные бициклического амида для усиления глутаматергических синаптических ответов
AU2010208646A AU2010208646A1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI1005316A BRPI1005316A2 (pt) 2009-02-02 2010-01-29 composto, composição farmacêuttca, métodos para tratamento e uso de um composto
JP2011547981A JP2012516845A (ja) 2009-02-02 2010-01-29 グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
SG2011054376A SG173168A1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
CA2751285A CA2751285A1 (fr) 2009-02-02 2010-01-29 Derives amides bicycliques permettant d'ameliorer les reponses synaptiques glutamatergiques
IL214392A IL214392A0 (en) 2009-02-02 2011-08-01 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
US61/206,642 2009-02-02

Publications (2)

Publication Number Publication Date
WO2010087981A2 WO2010087981A2 (fr) 2010-08-05
WO2010087981A3 true WO2010087981A3 (fr) 2011-03-24

Family

ID=42396261

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/000255 Ceased WO2010087981A2 (fr) 2009-02-02 2010-01-29 Dérivés amides bicycliques permettant d'améliorer les réponses synaptiques glutamatergiques
PCT/US2010/000254 Ceased WO2010087980A2 (fr) 2009-02-02 2010-01-29 Dérivés amides bicycliques pour le traitement de la dépression respiratoire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000254 Ceased WO2010087980A2 (fr) 2009-02-02 2010-01-29 Dérivés amides bicycliques pour le traitement de la dépression respiratoire

Country Status (12)

Country Link
EP (1) EP2391621A4 (fr)
JP (1) JP2012516845A (fr)
KR (1) KR20110115139A (fr)
CN (1) CN102369201A (fr)
AU (1) AU2010208646A1 (fr)
BR (1) BRPI1005316A2 (fr)
CA (1) CA2751285A1 (fr)
EA (1) EA018994B1 (fr)
IL (1) IL214392A0 (fr)
MX (1) MX2011008060A (fr)
SG (1) SG173168A1 (fr)
WO (2) WO2010087981A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035950A1 (fr) * 1997-02-13 1998-08-20 Cortex Pharmaceuticals, Inc. Composes a base de benzofurazan renforçant l'activite du recepteur de l'ampa
WO1999021422A1 (fr) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Traitement de la schizophrenie par ampakines et neuroleptiques
WO2008143963A1 (fr) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Amides disubstitués pour l'amélioration de réponses synaptiques glutamatergiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100303523B1 (ko) * 1992-07-24 2001-11-22 린다 에스. 스티븐슨 Ampa수용체에의해중재되는시냅스반응을증진하는약제
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
RU2010106975A (ru) * 2007-08-10 2011-09-20 Кортекс Фармасьютикалз, Инк. (Us) Бициклические амиды для усиления глутаматергических синаптических ответов

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035950A1 (fr) * 1997-02-13 1998-08-20 Cortex Pharmaceuticals, Inc. Composes a base de benzofurazan renforçant l'activite du recepteur de l'ampa
WO1999021422A1 (fr) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Traitement de la schizophrenie par ampakines et neuroleptiques
WO2008143963A1 (fr) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Amides disubstitués pour l'amélioration de réponses synaptiques glutamatergiques

Also Published As

Publication number Publication date
WO2010087980A2 (fr) 2010-08-05
JP2012516845A (ja) 2012-07-26
MX2011008060A (es) 2011-09-09
EA018994B1 (ru) 2013-12-30
CA2751285A1 (fr) 2010-08-05
SG173168A1 (en) 2011-08-29
IL214392A0 (en) 2011-09-27
EP2391621A4 (fr) 2012-07-25
BRPI1005316A2 (pt) 2019-09-24
EP2391621A2 (fr) 2011-12-07
EA201101162A1 (ru) 2012-01-30
AU2010208646A1 (en) 2011-09-01
WO2010087981A2 (fr) 2010-08-05
WO2010087980A3 (fr) 2011-02-24
CN102369201A (zh) 2012-03-07
KR20110115139A (ko) 2011-10-20

Similar Documents

Publication Publication Date Title
MX2009012430A (es) Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas.
WO2009023126A3 (fr) Amides bicycles permettant d&#39;améliorer les réponses synaptiques glutamatériques
WO2009038752A3 (fr) 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
TN2009000277A1 (en) 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses
IL225930B (en) Apparatus and method for detecting amyloid in a retina in a diagnosis, advancement, and prognosing of alzheimer&#39;s disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative dissorders, and ocular diseases
PL2318035T3 (pl) Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
MX2009004071A (es) Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos.
PT2349300T (pt) Terapia combinada para tratamento de doentes com distúrbios neurológicos e enfarte cerebral
IL215910A (en) Derivatives 4,2,1 - Triazolo [3,4 – a] Pyridine, pharmaceutical preparations contain them and processes for their preparation and their uses for the preparation of drugs for the treatment of diseases of the central nervous system
DOP2011000138A (es) Nuevos compuestos 578
JOP20220102A1 (ar) مثبطات المُسْتقبلة الأدرينِية adrac2
WO2009109493A3 (fr) 2-aminoquinolines
WO2008153958A3 (fr) Formes cristallines du composé (r)-1-{2-[4&#39;-(3-méthoxy-propane-1-sulfonyl)-biphényl-4-yl]-éthyl}-2-méthyl-pyrrolidine, et compositions et procédés associés
JP2010529130A5 (fr)
WO2010087981A3 (fr) Dérivés amides bicycliques permettant d&#39;améliorer les réponses synaptiques glutamatergiques
HUP0900231A2 (hu) Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
WO2009134668A3 (fr) Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine
EP2552473A4 (fr) Méthodes de traitement de la maladie de parkinson et autres troubles des neurones dopaminergiques du cerveau
WO2003045315A3 (fr) Composes carbonylbenzoxaziniques ameliorant les reponses synaptiques glutamatergiques
WO2007061741A3 (fr) Modulateurs du recepteur h3 utiles pour le traitement de troubles associes au dit recepteur
WO2011015646A3 (fr) Dérivés de furane-imidazolone pour le traitement de maladies ou troubles cognitifs, neurodégénératifs ou neuronaux
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
HK1126385A (en) Method and apparatus of noninvasive, regional brain thermal stimuli for the treatment of neurological disorders
TH102412A (th) สารควบคุมชนิดไบเฟนิลซัลโฟนิล และเฟนิล-เฮทเทโรแอริลซัลโฟนิลของฮีสทามีน h3-รีเซปเตอร์ที่มีประโยชน์สำหรับการรักษาความผิดปกติที่เกี่ยวข้องกับรีเซปเตอร์นั้น

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080015403.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008060

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 214392

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2751285

Country of ref document: CA

Ref document number: 2011547981

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 6059/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010736150

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010208646

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20117019461

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010208646

Country of ref document: AU

Date of ref document: 20100129

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 594954

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201101162

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736150

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI1005316

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110729